Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

187.85 -1.80 (-0.95%)
Official Closing Price Updated: 7:00 PM EDT, Oct 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,017,528
Open 189.68
Bid (Size) 186.98 (1)
Ask (Size) 187.85 (2)
Prev. Close 189.65
Today's Range 187.17 - 189.88
52wk Range 135.85 - 199.95
Shares Outstanding N/A
Dividend Yield 3.15%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Forecasting The Future: 11 Analyst Projections For AbbVie
Via Benzinga
3 High-Yielding Dividend Stocks That Can Be Ideal Buys for Retirees
These stocks yield between 2.8% and 3.3% in dividends. 
Via The Motley Fool

Performance

YTD
+17.54%
+17.54%
1 Month
-1.78%
-1.78%
3 Month
+1.45%
+1.45%
6 Month
+17.69%
+17.69%
1 Year
+29.37%
+29.37%

More News

Read More
Check Out What Whales Are Doing With ABBV
Via Benzinga
Beat the Nasdaq With This Cash-Gushing Dividend Stock
Via The Motley Fool
3 Simple Vanguard ETFs to Buy With $1,000 and Hold for a Lifetime
Via The Motley Fool
Topics ETFs
Market Analysis: AbbVie And Competitors In Biotechnology Industry
Via Benzinga
Looking Into AbbVie's Recent Short Interest
Via Benzinga
If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today
Via Benzinga
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
Via Talk Markets
3 Growth Stocks That Could Be Bargain Buys Right Now
Via The Motley Fool
FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year
Via Benzinga
Exposures Product Safety
AbbVie Is Doing 'Very Well' But Jim Cramer's Favorite? Abbott Laboratories
Via Benzinga
Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces
Via Benzinga
AbbVie's Options: A Look at What the Big Money is Thinking
Via Benzinga
In-Depth Examination Of 11 Analyst Recommendations For AbbVie
Via Benzinga
2 Magnificent Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
Best Pharma Stocks for Long-Term Investors: Growth and Dividends
Via MarketBeat
Prediction: These 2 High-Yield Dividend Stocks Will Outperform the S&P 500 Index in the Coming Decade
Via The Motley Fool
Topics Stocks
Exposures US Equities
Johnson & Johnson Dividend Stock Analysis - Saturday, Oct. 12
Via Talk Markets
There Are Only 28 S&P 500 Companies Warren Buffett Can't Buy Outright. Here's the Best of the Bunch for Income Investors.
Via The Motley Fool
Topics Stocks
Exposures US Equities
AbbVie Stock Eyes New Highs: Analysts See Strong Growth Potential
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
Via Benzinga
Biotech Stocks Poised For Another Big Move In Q4
Via Talk Markets
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
3 Magnificent Dividend Stocks to Buy in October
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.